• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:19:03 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials
    Get the next $CBUS alert in real time by email
    cbus-20250508
    0001705843FALSE00017058432024-05-082024-05-08

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ______________________
    FORM 8-K
    ______________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report: (Date of earliest event reported): May 8, 2025
    ______________________
    Cibus, Inc.
    (Exact name of registrant as specified in its charter)
    ______________________
    Delaware001-3816127-1967997
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    6455 Nancy Ridge Drive
    San Diego, CA
    92121
    (Address of principal executive offices)(Zip Code)
    (858) 450-0008
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former name or former address, if changed since last report)
    ______________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading
    Symbol(s)
    Name of exchange
    on which registered
    Class A Common Stock, $0.0001 par value per shareCBUSThe NASDAQ Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 2.02.     Results of Operations and Financial Condition.
    On May 8, 2025, Cibus, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2025, and provided a year-to-date business update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit
    Number
    Description
    99.1
    Press Release, dated May 8, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, Cibus, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Dated: May 8, 2025
    CIBUS, INC.
    By:/s/ Peter Beetham
    Name:Peter Beetham
    Title:Interim Chief Executive Officer

    Get the next $CBUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBUS

    DatePrice TargetRatingAnalyst
    7/29/2024$25.00Buy
    Alliance Global Partners
    7/19/2024$22.00Buy
    Canaccord Genuity
    10/9/2023$25.00Buy
    H.C. Wainwright
    7/19/2023$30.00Buy
    Canaccord Genuity
    More analyst ratings

    $CBUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

      Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture and Livestock in Ecuador determined that the Company's HT1 and HT3 Rice traits are equivalent to those developed through conventional breeding Disease resistance program advances with positive Sclerotinia data for multiple modes of action against Sclerotinia in Canola; Cibus' time bound and predictable RTDS tech

      5/8/25 4:05:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Ecuador Approves Cibus Herbicide Tolerance Traits as Equivalent to Conventional Breeding

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that the Ministry of Agriculture and Livestock in Ecuador has determined that Rice cultivars containing Cibus' herbicide tolerance Rice traits (HT1 and HT3) are equivalent to those developed through conventional breeding and subject to the same regulations as conventional seed in accordance with the provisions of the Organic Law of Agrobiodiversity, Seeds and Promotion of Sustainable Agriculture and its Regulations. The Rice trait products reviewed were developed utilizing Cibus' Rapi

      5/7/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2025 Results Conference Call Event Date: Thursday, May 8, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-1983 (U.S.), +1-785-838-9310 (International)The c

      4/25/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cibus Inc.

      10-Q - Cibus, Inc. (0001705843) (Filer)

      5/8/25 4:35:08 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      5/8/25 4:19:03 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • SEC Form DEFA14A filed by Cibus Inc.

      DEFA14A - Cibus, Inc. (0001705843) (Filer)

      4/10/25 4:45:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Research Sauer Noel was granted 11,750 shares, increasing direct ownership by 13% to 105,480 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      3/28/25 4:54:46 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • New insider Sauer Noel claimed ownership of 93,730 shares (SEC Form 3)

      3 - Cibus, Inc. (0001705843) (Issuer)

      3/28/25 4:50:18 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • CLO, Gen Csl & Secy Stokes Jason was granted 28,250 shares, increasing direct ownership by 28% to 127,669 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      3/28/25 4:38:32 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Cibus Global with a new price target

      Alliance Global Partners initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

      7/29/24 7:49:52 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Canaccord Genuity resumed coverage on Cibus Global with a new price target

      Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $22.00

      7/19/24 8:34:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • H.C. Wainwright initiated coverage on Cibus Global with a new price target

      H.C. Wainwright initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

      10/9/23 8:32:05 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    Financials

    Live finance-specific insights

    See more

    $CBUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

      Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture and Livestock in Ecuador determined that the Company's HT1 and HT3 Rice traits are equivalent to those developed through conventional breeding Disease resistance program advances with positive Sclerotinia data for multiple modes of action against Sclerotinia in Canola; Cibus' time bound and predictable RTDS tech

      5/8/25 4:05:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2025 Results Conference Call Event Date: Thursday, May 8, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-1983 (U.S.), +1-785-838-9310 (International)The c

      4/25/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call

      SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2024 Results Conference Call Event Date: Thursday, March 20, 2025         Time: 4:30 p.m. ET         Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317

      3/11/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jim Collins to Join Cibus Board of Directors

      Cibus Announces Election of New Board Member, Deepening Strategic Leadership and Experience SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of Directors has elected Jim Collins, former CEO of Corteva, to the Board. "Jim brings to Cibus immense knowledge and strategic vision on the direction of the future role and use of Gene Editing in agriculture," said Mark Finn, Chair of the Audit Committee. "Jim's experience leading one of the largest agricultural and seed companies will gi

      9/18/23 5:23:58 PM ET
      $ADM
      $CBUS
      Packaged Foods
      Consumer Staples
      Agricultural Chemicals
      Industrials
    • Steve Berreth Appointed as General Counsel and Corporate Secretary

      SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, announced today the appointment of Steve Berreth as General Counsel and Corporate Secretary for the corporation. Mr. Berreth was previously Vice President, General Counsel and Secretary for Syngenta Crop Protection LLC, the North American Subsidiary of Syngenta AG, one of the world's largest biotechnology agribusinesses and one of the largest crop protection chemical and seed businesses in the world. He was a member of the Syngenta global legal and compliance leadership teams and led the North American le

      8/3/23 12:30:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials